Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
The full clinical picture was first presented by Friedrich Wegener (1907–1990), a German pathologist, in two reports in 1936 and 1939, leading to the eponymous name Wegener's granulomatosis or Wegener granulomatosis (English: / ˈ v ɛ ɡ ə n ər /). [10]
Drug Dose Mode Days Rituximab: 375 mg/m 2: IV infusion: Day 1 Etoposide: 50 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Prednisolone: 60 mg/m 2: By mouth, twice a day (PO BID) Days 1–5 Oncovin: vincristine: 0.4 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Cyclophosphamide: 750 mg/m 2: IV bolus given over 15 min: Day 5 ...
According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion. [21]: 3, 7–8 Competition as well as potential for combination is expected from other drugs such as ibrutinib and idelalisib, both of which were also approved in 2014 to treat CLL. [21]: 7–8 [22]
Friedrich Wegener (7 April 1907, Varel – 9 July 1990, Lübeck, [veːɡɐnəɐ̯]) was a German pathologist who is notable for being a high-ranking Nazi physician and for his description of a rare disease originally referred to Wegener disease and now referred to as granulomatosis with polyangiitis. Although this disease was known before ...
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...
Drug Dose Mode Days Rituximab: 375 mg/m 2: IV infusion: Day 1 Ifosfamide: 5000 mg/m 2: IV continuous infusion over 24 hours: Day 2 Mesna for haemorrhagic cystitis prophylaxis with ifosfamide: 5000 mg/m 2: IV continuous infusion over 24 hours: Day 2 Carboplatin: Optimized to get AUC = 5 (max. 800 mg) IV infusion: Day 2 Etoposide: 100 mg/m 2: IV ...
In October 2008, the FDA granted further approval to market Treanda for the treatment of indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. [13]